KG
Thesis
The company has an excellent franchise in pain medications and is expected to recover its earnings and valuation despite current pressures from generic competition. With a pipeline of potential drugs nearing approval, the investment was made at a low multiple of demonstrated earnings, suggesting significant upside potential.
Did it work?
The thesis was a long recovery play expecting earnings and valuation re-rating plus pipeline-driven upside from a low earnings multiple. Instead, 28 months later the stock is down 24.3%, indicating the anticipated recovery never materialized and the 'low multiple' likely became a value trap as generic competition pressures persisted. A substantial decline over a multi-year period directly contradicts the thesis's stated upside expectation.